The 13th annual BIO-Europe Spring 2019 global life science partnering event will be held March 25–27 in Vienna, Austria. Guadalupe Rodriguez and Kit Muller of EBD Group report.
SPCs and trade secrets are just two issues set to be discussed at C5’s 11th Pharma & Biotech Patent Litigation, on February 26 and 27 in Amsterdam. LSIPR reports.
Hector Chagoya and Mariana Gonzalez-Vargas of Becerril, Coca & Becerril examine how Mexico applies the Budapest Treaty, which covers microorganisms in the patent process.
With several major drugs set to face generic or biosimilar competition as patent protection expires, LSIPR analyses how well prepared their manufacturers are and how badly their sales may be affected.
The implementation of precision medicine represents a huge, possibly unprecedented, challenge to conventional clinical practice across the breadth of healthcare disciplines, says Daniel Lim of Kirkland & Ellis.
An EU court ruling on gene-editing regulation has sparked widespread concerns in the scientific and legal communities, as LSIPR finds out.
Samsung and HP are just two technology companies that have diversified and invested in the life sciences industry. What impact will this type of activity have on the sector and will it be beneficial in the long run? LSIPR finds out.
The patenting of personalised healthcare inventions has proved problematic in a number of jurisdictions, but various aspects of these inventions are patentable in Europe, as Laurence Gainey of HGF explains.
Biologics patent owners should consider the US International Trade Commission as a supplement (or alternative) to district court litigation, say Filko Prugo, Charlotte Jacobsen, Matt Rizzolo and Henry Huang of Ropes & Gray.
A former Johnson & Johnson IP counsel and a retired judge are among the speakers at Life Sciences IP Due Diligence, on November 29 and 30 in Boston, as LSIPR finds out.